Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more than RMB 200 million (USD 29.1 million) in a Series B financing round. This significant investment, led by CCB Trust, will fuel the company’s efforts in advancing stem-cell drugs for a variety of diseases and expanding its technological capabilities.
Funding Allocation and Clinical Studies
The proceeds from the Series B financing round will be directed towards Phase I and Phase II clinical studies for stem-cell drugs targeting a range of conditions, including lung disease, degenerative joint disease, central nervous system diseases, and retinal congenital/degenerative diseases. These funds will also support the expansion of Zephyrm Bio’s technology platform and the construction of industrial-level cell production facilities, enhancing the company’s capacity to develop and manufacture stem-cell therapies at scale.
Zephyrm Bio’s Founding Team and Experience
Founded in 2018, Zephyrm Bioscience boasts a high-profile founder team with extensive executive experience in leading multinational companies such as Sanofi, Bayer, and Allergen. This wealth of experience positions the company well to navigate the complex regulatory and commercial landscapes of the biotechnology industry, particularly in the cutting-edge field of stem-cell drug development.
Conclusion
The successful Series B financing round for Zephyrm Bioscience is a testament to the company’s potential to revolutionize the treatment of various diseases through stem-cell therapies. With the backing of CCB Trust and the expertise of its founder team, Zephyrm Bio is well on its way to becoming a leader in the stem cell drug development sector.-Fineline Info & Tech
